1-Palmitoyl lysophosphatidic acid (1-Palmitoyl LPA) is a LPA analog containing palmitic acid at the sn-1 position. LPA binds to one of five different G protein-coupled receptors (GPCRs) to mediate a variety of biological responses including cell proliferation, smooth muscle contraction, platelet aggregation, neurite retraction, and cell motility. In addition to playing a role in the aforementioned biological responses, 1-palmitoyl LPA enhances the action of β-lactam antibiotics (ampicillin, piperacillin, and ceftazidime) on various strains of Pseudomonas aeruginosa, a pathogen associated with pulmonary disease and pneumonia, via binding both Ca2+ and Mg2+.
BLI-489 hydrate 是一种青霉烯类 β-内酰胺酶抑制剂,能够作用于 A 类和 C 类以及一些 D 类 β-内酰胺酶。Piperacillin 与 BLI-489 hydrate 联用,能够有效治疗 A 类 (包括超广谱 β-内酰胺酶)、C 类 (AmpC) 和 D 类 β-内酰胺酶表达病原体引起的小鼠感染。
1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PA (1-palmitoyl-d9LPA) serves as an internal standard for the quantification of 1-palmitoyl LPA using GC- or LC-MS. This compound, an analog of LPA with palmitic acid at the sn-1 position, activates reporter gene expression in PC12 cells fitted with human lysophosphatidic acid receptor 4 (LPA4) at 0.01 to 10 µM concentrations. Additionally, 1-palmitoyl LPA prompts aggregation in isolated human platelets within the 12-300 µM range, a process reversible by prostaglandin E1 (PGE1), theophylline, or EDTA. It also interacts with calcium and magnesium to boost the efficacy of ampicillin, piperacillin, and ceftazidime against P. aeruginosa strains from cystic fibrosis patients.